News

Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced that it has signed a…
Read More...

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing…
Read More...

Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we…
Read More...

Vesselon (www.vesselon.com), an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent®. Vesselon will use Imagent to create novel therapeutic…
Read More...

Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. announced that the two companies entered into a definitive merger agreement under which Aquinox agreed to the acquisition…
Read More...

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven…
Read More...

A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first…
Read More...

Stoke Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product candidate, STK-001, an investigational new…
Read More...

GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire,…
Read More...

Bayer and LANXESS sell their stakes in the chemical park operator Currenta to funds managed by Macquarie Infrastructure and Real Assets (MIRA), the world's largest infrastructure…
Read More...

Roche announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq (atezolizumab)…
Read More...

Eli Lilly and Company announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of…
Read More...

HCL Technologies (HCL), a leading global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences announced a collaboration to help…
Read More...

Neuropore Therapies, Inc. announced that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were…
Read More...

Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in…
Read More...

Sosei Group Corporation announces that it has entered into a strategic multi-target partnership with Takeda Pharmaceutical Company Limited, to discover, develop and commercialize novel…
Read More...

Alnylam Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for givosiran, an investigational RNAi…
Read More...

Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) approved TURALIO (pexidartinib) as the first and only treatment…
Read More...

Omeros Corporation announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding…
Read More...